Journal of Clinical MicrobiologyGenomicsPeer-reviewed journal article
Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool that Exploits Genomic Data in Public Health and Clinical Microbiology Applications
Charlene M.C. RodriguesiD, Keith A. JolleyiD, Andrew J. SmithiD, J. Claire CameroniD, Ian M. FeaversiD, Martin C. J. MaideniD
Abstract
As microbial genomics makes increasingly important contributions to clinical and public health microbiology, the interpretation of whole genome sequence data by non-specialists becomes essential. In the absence of capsule-based vaccines, two protein-based vaccines have been used for the prevention of invasive serogroup B meningococcal disease (IMD), since their licensure in 2013/14. These vaccines have different components and different coverage of meningococcal variants. Hence, decisions regarding which vaccine to use in managing serogroup B IMD outbreaks require information about the index case isolate including: (i) the presence of particular vaccine antigen variants; (ii) the expression of vaccine antigens; and (iii) the likely susceptibility of its antigen variants to antibody-dependent bactericidal killing. To obtain this information requires a multitude of laboratory assays, impractical in real-time clinical settings, where the information is most urgently needed. To facilitate assessment for public health and clinical purposes, we synthesised genomic and experimental data from published sources to develop and implement the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index, which is publicly-available on PubMLST (https://pubmlst.org). Using whole genome sequences or individual gene sequences obtained from IMD isolates or clinical specimens, MenDeVAR provides rapid evidence-based information on the presence and possible immunological cross-reactivity of different meningococcal vaccine antigen variants. The MenDeVAR Index enables practitioners who are not genomics specialists to assess the likely reactivity of vaccines for individual cases, outbreak management, or the assessment of public health vaccine programmes. MenDeVAR has been developed in consultation with, but independently of, both vaccine manufacturers.
- assay: whole-genome sequencing
- research focus: benchmarking
- research focus: database / resource
- research focus: software / tool
- approach: statistical model
- Citations
- 61
- FWCI
- 5.78
- Field percentile
- top 3%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- New strategy to select cross-reactivity Meningococci strains: immunization with Outer membrane vesicles of serogroup C and cationic lipid as adjuvant
A. I. Portilho, G. Trzewikowski de Lima, E. De Gaspari·bioRxiv·May 17, 2021
- Rationally designed minimized TbpB confers broad protection against meningococcal infection
Epshita A. Islam, Jamie E. Fegan, … Scott D. Gray‐Owen·PLoS PathogensPeer-reviewed·Aug 10, 2026
- Towards a Chimeric Vaccine against Multiple Isolates of Mycobacteroides - An Integrative Approach
Rohit Satyam, Tulika Bhardwaj, … Parma Nand·Life SciencesPeer-reviewed·Mar 10, 2020
- Phylogeny-based selection of representative variants with Navargator: Proof of principle using humoral cross-reactivity data from two immunization studies
David M. Curran, Dixon Ng, … Jamie E. Fegan·bioRxiv·Sep 8, 2024
- Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens
M. Troisi, M. Fabbrini, … An·bioRxiv·Dec 7, 2023
- The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
I. Leduc, K. L. Connolly, … A. Jerse·PLOS PathogensPeer-reviewed·Dec 8, 2020